Literature DB >> 9457982

Morphologic hysteroscopic criteria suggestive of endometrial hyperplasia.

L H Uno1, O Sugimoto, F M Carvalho, V R Bagnoli, A M Fonseca, J A Pinotti.   

Abstract

OBJECTIVES: To evaluate the morphologic hysteroscopic criteria leading to a diagnosis of endometrial hyperplasia and compare their accuracy with that of histology.
METHODS: A total of 95 hysteroscopic examinations were evaluated. Of these, 37 had a histologic diagnosis of normal endometrium and the remaining 58 of simple or complex endometrial hyperplasia. We compared the morphologic hysteroscopic criteria for the two groups using Pearson's chi-squared and Fisher's exact test.
RESULTS: Only the presence of endometrial glands presenting a cystic pattern at hysteroscopy gave statistically significant results (P < 0.05), with low sensitivity (15.79%), high specificity (97.29%) and a relative risk of 6.75. With a prevalence of endometrial hyperplasia of 22.97% in a population of women with metrorrhagia, the positive predictive value was 63.53% and the negative predictive value was 79.40%.
CONCLUSION: Additional, prospective studies are needed to determine the real value of the diagnostic morphologic parameters under consideration.

Entities:  

Mesh:

Year:  1995        PMID: 9457982     DOI: 10.1016/0020-7292(94)02303-g

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  2 in total

1.  Establishing patterns on hysteroscopy in abnormal uterine bleeding (AUB).

Authors:  Deeksha Pandey; Srividya Kunamneni; Pranadeep Reddy Inukollu; Hsuan Su
Journal:  Gynecol Minim Invasive Ther       Date:  2017-08-26

Review 2.  Hysteroscopy in the management of endometrial hyperplasia and cancer in reproductive aged women: new developments and current perspectives.

Authors:  Salvatore Giovanni Vitale; Gaetano Riemma; Jose Carugno; Benito Chiofalo; George Angelos Vilos; Stefano Cianci; Mehmet Sukru Budak; Bernardo Portugal Lasmar; Antonio Raffone; Ilker Kahramanoglu
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.